Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose [2]

Journal of Clinical Psychiatry

Volumn 62, Issue 12, 2001, Pages 993-994

  Van Meter, S A ^a   Seaburg, H ^a   McLendon, B ^a   Doraiswamy, P M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; HEMOGLOBIN A1C; INSULIN; MOLINDONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

ADULT; BLOOD GLUCOSE MONITORING; CASE REPORT; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LETTER; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHIZOIDISM; SEDATION; SUICIDAL BEHAVIOR;

EID: 0035658150     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n1214b     Document Type: Letter

References (5)

1. Olanzapine: A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses
2. Severe hyperglycemia associated with high doses of clozapine
3. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study
4. New onset diabetes and atypical antipsychotics
5. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses